Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD)
as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Background Varying conceptualizations of treatment‐resistant depression (TRD) have made
translating research findings or systematic reviews into clinical practice guidelines …

Major depressive disorder is a leading cause of disability worldwide. Because conventional
therapies are ineffective in many patients, novel strategies are needed to overcome …

Background Treatment‐resistant depression (TRD) is a debilitating chronic mental illness
that confers increased morbidity and mortality, decreases the quality of life, impairs …

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that modulates neuroplasticity in
the brain, and is one of the most widely investigated molecule in psychiatric disorders. The …

Precision medicine is increasingly recognized as a promising approach to improve disease
treatment, taking into consideration the individual clinical and biological characteristics …

A high proportion of depressed patients fail to respond to antidepressant drug treatment.
Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of …

Background Major depressive disorder is a common, recurrent, disabling and costly disorder
that is often severe and/or chronic, and for which non-remission on guideline concordant first …